✉news HealthMedicine first seen 20 h ago, last 3 h ago, peak #6

Laverock Therapeutics Expands into In Vivo CAR-T and Genetic Medicine

Original: Cell Therapy Weekly: Laverock Therapeutics Expands to In Vivo CAR-T and Genetic Medicine

Laverock Therapeutics announced an expansion of its work into in vivo CAR-T cell therapy and broader genetic medicine, according to Cell Therapy Weekly coverage. The move signals the company's ambition to move beyond ex vivo approaches and broaden its therapeutic pipeline, drawing attention from the regenerative medicine and cell therapy community.

Why now: The biotech sector is closely watching companies expanding CAR-T technology toward in vivo delivery, a potential shift in how cell therapies are made.

Laverock TherapeuticsRegMedNet

Open on news →

Rank over time, top of the chart is #1. 2 snapshots from 5 h ago to 3 h ago.

Evidence

• Cell Therapy Weekly: Laverock Therapeutics Expands to In Vivo CAR-T and Genetic Medicine · RegMedNet

API: https://socialmediatrends-api.osmike.com/v1/trends/672590